TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06540846

Intervention type: OTHER
Intervention: No intervention
Description: No intervention since this is an observational study

Intervention type: OTHER
Intervention: No intervention
Description: No intervention since this is an observational study
Study: NCT06315634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 5 micrograms intrathecal dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2 milligrams intrathecal midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: 12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine
Study: NCT04996212

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Walking APP Group
Description: The participants of this group will be explained their treatment plan by a physiotherapist who will contact them through a video call. This treatment will consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of aerobic exercise: walking.~Participants will consult their treatment plan through an application that will be installed on their mobile phone. They will start with 25 minutes of walking and will increase progressively until they reach 45 minutes.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment.~Participants must perform the proposed exercises, 5 days a week, once a day In addition to the respiratory physiotherapy guideline, they will be given the health education manual.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional APP group
Description: The participants of this group will be explained their treatment regimen by a physiotherapist who will contact them through a video call. This treatment planwill consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of functional exercise which involve the activation and performance of large muscle groups. Participants will consult their treatment plan through an application that will be installed on their mobile phone.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment.
Study: NCT06309069

Intervention type: OTHER
Intervention: None, purely observational study
Description: None, purely observational study
Study: NCT05141110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1705
Description: NVP-1705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1705-R
Description: NVP-1705-R
Study: NCT06302075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One Day Rehabilitation
Description: Patient discharged at home the day after the operation and carrying out outpatient rehabilitation according to the clinical standard

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fast Rehabilitation
Description: Patient discharged to the rehabilitation department of the Institute 48 hours after surgery which carries out rehabilitation during the hospital stay according to the clinical standard
Study: NCT06550817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Growth mindset intervention
Description: Online intervention is implemented and it lasts about 20 minutes each time, while face-to-face intervention lasts about 30 minutes each time, and they are carried out for a total of six weeks, face-to-face or telephone intervention is implemented once every two weeks for about 15 minutes each time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-health Program
Description: face-to-face e-health teaching in the first 6 weeks, and telephone follow-up were conducted once a week, for about 10 minutes each time in the last 6 weeks
Study: NCT03785158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liquid Melatonin
Description: Melatonin is a natural supplement.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar looking/tasting placebo syrup
Study: NCT05672706

Intervention type: PROCEDURE
Intervention: CFR and IMR group
Description: Participants will undergo repeat intracoronary adenosine administration during CFR and IMR measurement
Study: NCT05200676

Intervention type: DEVICE
Intervention: ePatch
Description: ePatch registers the heart rate continuously when attached to the chest of the participant.

Intervention type: DEVICE
Intervention: ePatch
Description: ePatch registers the heart rate continuously when attached to the chest of the participant.
Study: NCT06265402

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tab block versus retrolaminar block in abdominal plastic surgery
Description: i inject 20ml bupivacine either 4mg dead in each side

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tab block versus retrolaminar block in abdominal plastic surgery
Description: i inject 20ml bupivacine either 4mg dead in each side
Study: NCT06347081

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nd- YAG laser at 532nm wavelength
Description: Nd-YAG laser at 532nm wavelength every 2 weeks for 14 sessions. patients will also receive standard medical care, nursing, physiotherapy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nd- YAG laser at 532nm wavelength
Description: Nd-YAG laser at 532nm wavelength every 2 weeks for 14 sessions. patients will also receive standard medical care, nursing, physiotherapy
Study: NCT06101264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Intervention
Description: Participants will be given a virtual reality (VR) intervention following corrective scoliosis surgery for adolescent idiopathic scoliosis. The VR intervention will utilize a commercial device manufactured by Oculus. The intervention will utilize a software that simulates a low-physical load environment for the user. Starting on postoperative day 1, the participant will receive a 20-minute VR intervention 30 minutes prior to each physical therapy session. There will be two physical therapy sessions daily. Outcome measures will be assessed before and after every VR intervention and after the physical therapy session. The VR interventions will continue for each postoperative day until the participant is discharged from the hospital.
Study: NCT06125821

Intervention type: OTHER
Intervention: questionnaire
Description: questionnaire
Study: NCT05954481

Intervention type: OTHER
Group type: OTHER
Intervention: Stress echocardiography
Description: After a rest trans thoracic echocardiography (usual follow-up), eligible patients will have a stress ultrasound echocardiography on a dedicated cycle ergometer

Intervention type: OTHER
Group type: OTHER
Intervention: Stress echocardiography
Description: After a rest trans thoracic echocardiography (usual follow-up), eligible patients will have a stress ultrasound echocardiography on a dedicated cycle ergometer
Study: NCT06107465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: high dose Nitroglycerin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: high dose Nitroglycerin
Study: NCT05713032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed radiofrequency on lumbar dorsal root ganglion
Description: voltage of pulsed radiofrequency on DRG

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed radiofrequency on lumbar dorsal root ganglion
Description: voltage of pulsed radiofrequency on DRG
Study: NCT05154448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Thermal Ablation of the Medial Branch Nerves (Neurolyser XR)
Description: Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Sham procedure done in an identical manner to the treatment arm, but without deploying acoustical energy
Study: NCT05538507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: smart soup
Description: Severe AD, mild or moderate AD and MCI will be given smart soup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: smart soup
Description: Severe AD, mild or moderate AD and MCI will be given smart soup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: smart soup
Description: Severe AD, mild or moderate AD and MCI will be given smart soup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Severe AD and mild or moderate AD will be given donepezil

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Donepezil
Description: Severe AD and mild or moderate AD will be given donepezil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Severe AD and mild or moderate AD will be given donepezil

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Donepezil
Description: Severe AD and mild or moderate AD will be given donepezil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Severe AD will be given memantine
Study: NCT05755880

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal dexamethason
Description: After general anesthesia intrathecal dexamthasone will be added
Study: NCT04618211

Intervention type: DRUG
Group type: OTHER
Intervention: Deucrictibant
Description: deucrictibant soft capsules for oral use

Intervention type: DRUG
Group type: OTHER
Intervention: Deucrictibant
Description: deucrictibant soft capsules for oral use

Intervention type: DRUG
Group type: OTHER
Intervention: Deucrictibant
Description: deucrictibant soft capsules for oral use

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Matching placebo capsules for oral use

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Matching placebo capsules for oral use

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Matching placebo capsules for oral use
Study: NCT06132373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer delivered problem solving therapy
Description: PST uses a straightforward approach amenable to use in new settings given its focus on idiographic problems, therefore session content is driven by the adolescent's presenting problem causing the most distress or impairment. We will use the standardized, core steps of PST and existing manualized protocols including from the Friendship Bench study and the WHO protocol for Problem Management Plus. The peers will deliver PST through 5 structured counseling sessions of 30-60 minutes over a 4-6 week period. There are 5 core components of PST which including problem listing and identification, problem exploration, developing an action plan, implementation, and follow up. The components will be introduced in the first session and be reviewed in an iterative process across the session to help participants use this model for different problems.
Study: NCT05190445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel
Description: HER2/4-1BB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinrebafusp alfa (PRS-343) in combination with tucatinib
Description: HER2/4-1BB
Study: NCT05405816

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic sleeve gastrectomy
Description: laparoscopic sleeve gastrectomy for obesity
Study: NCT06528379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The exercise programme is a 6-month progressive tailored-based exercise regime comprising~* aerobic exercises (40-60%)~* resistance exercises (20-40%)~* balance with resistance exercises (20%) .~This is peformed 3 times weekly, it is tailored to each individual but delivered in a small group-based manner. Two sessions are supervised by physiotherapist /exercise scientist and one session is unsupervised, home-based.
Study: NCT05132621

Intervention type: DIAGNOSTIC_TEST
Intervention: Smear
Description: A smear of the posterior vaginal fornix collected with a gynecological speculum.

Intervention type: DIAGNOSTIC_TEST
Intervention: Smear
Description: A smear of the posterior vaginal fornix collected with a gynecological speculum.

Intervention type: DIAGNOSTIC_TEST
Intervention: Smear
Description: A smear of the posterior vaginal fornix collected with a gynecological speculum.
Study: NCT05546684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: footbath
Description: footbath for patients before sleeping
Study: NCT05538507

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Memantine
Description: Severe AD will be given memantine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: patients with MCI will be given placebo
Study: NCT05417932

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCG101
Description: Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
Study: NCT05307653

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Penile block
Description: Penile block was performed in supine position. The penis was retracted caudally and then fixed with a leucoplast. After identifying the symphysis pubis (SP), a 22-gauge needle was inserted vertically about 1 cm lateral to the SP, and bupivacaine 0.5% (0.1 ml/kg, maximum 2.5 ml) was injected on each side after penetrating the Scarpa's fascia.
Study: NCT05538507

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: patients with MCI will be given placebo

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: patients with MCI will be given placebo
Study: NCT05521581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand massage
Description: Hand massage will be applied to primiparous mothers who gave birth by cesarean section and its effect on pain, comfort and gas release times will be evaluated.
Study: NCT05870384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy
Description: Ten sessions of IPT-G, which focuses on the common problem area of patient relatives, will be applied.
Study: NCT05307653

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinea plain block
Description: Ultrasound guided ESPB was performed in prone position by Philips © (CX50 Extreme edition). The superficial probe was placed longitudinally at the midline just above the sacrum, and both erector spinae muscles and median sacral crests were identified. Using the in-plane approach, a 22-gauge needle was inserted in a craniocaudal direction till reaching the tip of the fourth median sacral crest. After negative aspiration to avoid intravascular or intrathecal puncture, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered.
Study: NCT05091307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Ad26.COV2.S will be administered as an IM injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ad26.COV2.S
Description: Ad26.COV2.S will be administered as an IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Ad26.COV2.S will be administered as an IM injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ad26.COV2.S
Description: Ad26.COV2.S will be administered as an IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an IM injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as an IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an IM injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as an IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: Influenza vaccine high and standard dose will be administered as IM injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza Vaccine
Description: Influenza vaccine high and standard dose will be administered as IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: Influenza vaccine high and standard dose will be administered as IM injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza Vaccine
Description: Influenza vaccine high and standard dose will be administered as IM injection.
Study: NCT06225089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pericapsuler nerve block
Description: -Ultrasound Guided pericapsuler nerve block: will be externally rotated and abducted to 45 degrees. The shoulder area will be sterilized with povidone-iodine. High-frequency linear ultrasound perpendicularly between the coracoid and the humeral head probe. The deltoid muscle, subscapular muscle and tendon, and humeral head will be identified on the ultrasound screen. With the in-plane technique, a 22 gauge, 50 millimeter (mm) simplex A peripheral nerve block needle will be used. After passing the deltoid muscle, the needle will contact the tendon of the subscapularis muscle. The needle will be slightly withdrawn and directed between the deltoid muscle and the tendon of the subscapularis muscle and a local injection consisting of will be applied.
Study: NCT06502288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 625 mg of amoxicillin with combined clavulanic acid tablet
Description: The intervention group must take 625 mg of amoxicillin with combined clavulanic acid tablets three times a day after meals for 7 days following extraction.
Study: NCT05697042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MY-Skills for Long COVID
Description: 8 week online intervention with therapeutic yoga and self-management education
Study: NCT05371600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam IV at 0.04 mg/kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: an equal volume of saline IV
Study: NCT05884697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: K-Talk Intervention (Storytelling and K-Bot)
Description: The K-Talk intervention group receives a combination of a storytelling intervention and an artificial intelligence chatbot (K-Bot) education.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Storytelling Intervention
Description: The storytelling intervention features 12 authentic stories from young Korean immigrants and Americans. Each video is about 3 minutes long and includes stories from 1st, 1.5, and 2nd generation young Korean individuals, highlighting their perceptions of HPV and HPV vaccines, and their experiences with HPV vaccination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: K-Bot Intervention
Description: The K-Bot intervention is a conversational and button-based artificial intelligence Chatbot that is available in both English and Korean.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Information
Description: The written information provided includes the Centers for Disease Control and Prevention's (CDC) details on HPV and HPV vaccines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Information
Description: The written information provided includes the Centers for Disease Control and Prevention's (CDC) details on HPV and HPV vaccines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Information
Description: The written information provided includes the Centers for Disease Control and Prevention's (CDC) details on HPV and HPV vaccines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written Information
Description: The written information provided includes the Centers for Disease Control and Prevention's (CDC) details on HPV and HPV vaccines.
Study: NCT05307653

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal block
Description: Caudal block was performed in the left lateral position. A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed. When no blood or cerebrospinal fluid was observed, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered. The patient was returned to the supine position after the procedure was completed.
Study: NCT05494346

Intervention type: DEVICE
Group type: OTHER
Intervention: Measurement of peak nasal flow.
Description: Peak nasal flow measurements will be performed before and after the first use of the spray at D0, as well as after the use of the spray at the medical office at D3 (only for arm A).
Study: NCT06473571

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Protocol (The 3GT)
Description: Participants will be asked to identify three things that went well that day and their role for this occurring \[What went well today, and what was your role in making it happen? as adapted from (Sexton \& Adair, 2019)\]. They will be asked to engage in this exercise for 15 days during the evening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants will be asked to reflect on early memories of their life, with no specific prompts provided, for 15 days during the evening. This activity is consistent with prior efficacy studies of 3GT (Seligman et al., 2005).
Study: NCT06426511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab+Chemotherapy
Description: After surgical resection, patients received 4 cycle of toripalimab (240 mg) in combination with platinum-based adjuvant treatment. Administration of standard postoperative adjuvant chemotherapy for stage IB disease was not mandatory; decisions about whether patients with IB disease would receive adjuvant chemotherapy were made by the physicians.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab+Chemotherapy followed by consolidation toripalimab
Description: After surgical resection, patients received 4 cycle of toripalimab (240 mg) in combination with platinum-based adjuvant treatment, and then maintenance treatment with single-agent toripalimab (240 mg) once every 3 weeks for up to 13 cycles.~Administration of standard postoperative adjuvant chemotherapy for stage IB disease was not mandatory; decisions about whether patients with IB disease would receive adjuvant chemotherapy were made by the physicians.